Sequential P‐GEMOX and radiotherapy for early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter study

Extranodal natural killer/T‐cell lymphoma, nasal‐type (ENKTL) is a distinct subtype of non‐Hodgkin lymphoma and most of the patients presented localized disease. Combined modality therapy (CMT), namely chemotherapy combined with radiotherapy, has been recommended for patients with early‐stage ENKTL....

Full description

Saved in:
Bibliographic Details
Published in:American journal of hematology 2021-11, Vol.96 (11), p.1481-1490
Main Authors: Zhang, Yuchen, Ma, Shuyun, Cai, Jun, Yang, Yu, Jing, Hongmei, Shuang, Yuerong, Peng, Zhigang, Li, Bingzong, Liu, Panpan, Xia, Zhongjun, Xia, Yi, Gao, Yan, Chen, Daoguang, Lin, Jianyang, Li, Qihui, Xu, Shenghua, Xu, Qingyuan, Zhang, Han, Huang, Huiqiang, Cai, Qingqing
Format: Article
Language:English
Subjects:
Chemotherapy
Gemcitabine
Hematology
Lymphoma
Medical prognosis
Multivariate analysis
Natural killer cells
Nomograms
Non-Hodgkin's lymphoma
Oxaliplatin
Patients
Population distribution
Radiation therapy
Remission
T-cell lymphoma
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Extranodal natural killer/T‐cell lymphoma, nasal‐type (ENKTL) is a distinct subtype of non‐Hodgkin lymphoma and most of the patients presented localized disease. Combined modality therapy (CMT), namely chemotherapy combined with radiotherapy, has been recommended for patients with early‐stage ENKTL. However, the optimal CMT has not been fully clarified. This study reports the efficacy and toxicity of sequential P‐GEMOX (pegaspargase, gemcitabine and oxaliplatin) and radiotherapy in a large Chinese cohort comprising of 202 patients diagnosed with early‐stage ENKTL from six medical centers. The observed best overall response rate was 96.0% and 168 (83.2%) patients achieved complete remission. With a median follow‐up of 44.1 months, the 3‐year progression‐free survival (PFS) and overall survival (OS) were 74.6% and 85.2%, respectively. Multivariate analysis suggested that extensive primary tumor (PFS, hazard ratio [HR] 3.660, 95% CI 1.820–7.359, p <  0.001; OS, HR 3.825, 95% CI 1.442–10.148, p = 0.007) and Eastern Cooperative Oncology Group performance status ≥ 2 (PFS, 3.042, 95% CI 1.468–6.306, p = 0.003; OS, HR 3.983, 95% CI 1.678–9.457, p = 0.02) were independent prognostic factors for survival outcomes. Among the established prognostic models for ENKTL, the nomogram‐revised risk index model had optimal prognostic risk stratification ability (PFS, p 
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.26335